Aptose Biosciences Inc. Files 8-K: Material Agreement
Ticker: APTOF · Form: 8-K · Filed: Nov 25, 2024 · CIK: 882361
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Aptose Biosciences Inc. signed a big deal on Nov 21, 2024. 8-K filed.
AI Summary
On November 21, 2024, Aptose Biosciences Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements and exhibits. Aptose Biosciences Inc. is incorporated in Canada and its fiscal year ends on December 31.
Why It Matters
This 8-K filing indicates Aptose Biosciences Inc. has entered into a significant new agreement, which could impact its business operations and financial future.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities that are not yet fully understood.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- November 21, 2024 (date) — Date of earliest event reported
- Canada (location) — State or other jurisdiction of incorporation
- 001-32001 (other) — SEC file number
FAQ
What type of material definitive agreement did Aptose Biosciences Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on November 21, 2024.
What is the primary business of Aptose Biosciences Inc.?
Aptose Biosciences Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When is Aptose Biosciences Inc.'s fiscal year end?
Aptose Biosciences Inc.'s fiscal year ends on December 31.
What is the SEC file number for Aptose Biosciences Inc.?
The SEC file number for Aptose Biosciences Inc. is 001-32001.
Has Aptose Biosciences Inc. changed its name previously?
Yes, Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. (name change on 20140905), which was formerly known as Imutec Pharma Inc. (name change on 19970113).
Filing Stats: 1,307 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2024-11-25 16:27:00
Key Financial Figures
- $0.25 — n share at an initial exercise price of $0.25 per share. The public offering price
- $0.20 — share and accompanying half warrant was $0.20. The securities were offered and sold
- $8,000,000, b — ate gross proceeds from the offering of $8,000,000, before deducting placement agent's fees a
- $10,000 — -accountable expense allowance of up to $10,000 and reimburse the Placement Agent's leg
- $60,000 — al fees and expenses in an amount up to $60,000. The Company has also agreed to issue
- $0.275 — suance, at an initial exercise price of $0.275. The Placement Agent Warrants and the
Filing Documents
- d886997d8k.htm (8-K) — 34KB
- d886997dex41.htm (EX-4.1) — 80KB
- d886997dex42.htm (EX-4.2) — 83KB
- d886997dex101.htm (EX-10.1) — 40KB
- d886997dex991.htm (EX-99.1) — 9KB
- g886997g1125224013734.jpg (GRAPHIC) — 4KB
- 0001193125-24-265193.txt ( ) — 440KB
- apto-20241121.xsd (EX-101.SCH) — 3KB
- apto-20241121_lab.xml (EX-101.LAB) — 18KB
- apto-20241121_pre.xml (EX-101.PRE) — 11KB
- d886997d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Common Warrant 4.2 Form of Placement Agent Warrant 10.1 Placement Agency Agreement, dated as of November 21, 2024, by and among Aptose Biosciencs Inc. and A.G.P./Alliance Global Partners, as placement agent. 99.1 Press Release dated November 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: November 25, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. President and Chief Executive Officer